- Home
- DBRG vs GLPG Comparison
DBRG vs GLPG Comparison
Compare DBRG & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- GLPG
- Stock Information
- Founded
- DBRG 1991
- GLPG 1999
- Country
- DBRG United States
- GLPG Belgium
- Employees
- DBRG N/A
- GLPG N/A
- Industry
- DBRG Real Estate Investment Trusts
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- GLPG Health Care
- Exchange
- DBRG Nasdaq
- GLPG Nasdaq
- Market Cap
- DBRG 2.0B
- GLPG 1.8B
- IPO Year
- DBRG 2009
- GLPG 2005
- Fundamental
- Price
- DBRG $12.15
- GLPG $26.74
- Analyst Decision
- DBRG Strong Buy
- GLPG Sell
- Analyst Count
- DBRG 9
- GLPG 5
- Target Price
- DBRG $16.67
- GLPG $26.75
- AVG Volume (30 Days)
- DBRG 2.6M
- GLPG 355.9K
- Earning Date
- DBRG 02-20-2025
- GLPG 02-12-2025
- Dividend Yield
- DBRG 0.33%
- GLPG N/A
- EPS Growth
- DBRG N/A
- GLPG N/A
- EPS
- DBRG 0.07
- GLPG 1.16
- Revenue
- DBRG $607,028,000.00
- GLPG $285,380,474.00
- Revenue This Year
- DBRG N/A
- GLPG $2.78
- Revenue Next Year
- DBRG N/A
- GLPG $1.62
- P/E Ratio
- DBRG $67.56
- GLPG $23.02
- Revenue Growth
- DBRG N/A
- GLPG 14.99
- 52 Week Low
- DBRG $10.04
- GLPG $22.36
- 52 Week High
- DBRG $19.49
- GLPG $37.22
- Technical
- Relative Strength Index (RSI)
- DBRG 65.50
- GLPG 71.20
- Support Level
- DBRG $10.04
- GLPG $26.49
- Resistance Level
- DBRG $12.63
- GLPG $27.48
- Average True Range (ATR)
- DBRG 0.56
- GLPG 0.66
- MACD
- DBRG 0.19
- GLPG 0.54
- Stochastic Oscillator
- DBRG 81.50
- GLPG 85.55
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.